These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 17631252

  • 1. Alpha4-integrin antagonism--an effective approach for the treatment of inflammatory diseases?
    Davenport RJ, Munday JR.
    Drug Discov Today; 2007 Jul; 12(13-14):569-76. PubMed ID: 17631252
    [Abstract] [Full Text] [Related]

  • 2. Natalizumab: targeting alpha4-integrins in multiple sclerosis.
    Engelhardt B, Kappos L.
    Neurodegener Dis; 2008 Jul; 5(1):16-22. PubMed ID: 18075270
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
    Rudick RA, Sandrock A.
    Expert Rev Neurother; 2004 Jul; 4(4):571-80. PubMed ID: 15853576
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn's disease.
    Ko HH, Bressler B.
    Expert Rev Gastroenterol Hepatol; 2007 Oct; 1(1):29-39. PubMed ID: 19072431
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Drug insight: using monoclonal antibodies to treat multiple sclerosis.
    Hohlfeld R, Wekerle H.
    Nat Clin Pract Neurol; 2005 Nov; 1(1):34-44. PubMed ID: 16932490
    [Abstract] [Full Text] [Related]

  • 11. [Natalizumab: an antibody targeting α4-integrin].
    Nakahara J.
    Brain Nerve; 2014 Oct; 66(10):1149-58. PubMed ID: 25296869
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Multiple sclerosis and Natalizumab.
    Fiore D.
    Am J Ther; 2007 Oct; 14(6):555-60. PubMed ID: 18090880
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Alpha4 integrins as therapeutic targets in autoimmune disease.
    von Andrian UH, Engelhardt B.
    N Engl J Med; 2003 Jan 02; 348(1):68-72. PubMed ID: 12510047
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Novel treatment options for inflammatory bowel disease: targeting alpha 4 integrin.
    Lanzarotto F, Carpani M, Chaudhary R, Ghosh S.
    Drugs; 2006 Jan 02; 66(9):1179-89. PubMed ID: 16827596
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.